[go: up one dir, main page]

MX2009014001A - Derivados de isoxazol-imidazol. - Google Patents

Derivados de isoxazol-imidazol.

Info

Publication number
MX2009014001A
MX2009014001A MX2009014001A MX2009014001A MX2009014001A MX 2009014001 A MX2009014001 A MX 2009014001A MX 2009014001 A MX2009014001 A MX 2009014001A MX 2009014001 A MX2009014001 A MX 2009014001A MX 2009014001 A MX2009014001 A MX 2009014001A
Authority
MX
Mexico
Prior art keywords
sup
imidazole derivatives
isoxazole
present
concerned
Prior art date
Application number
MX2009014001A
Other languages
English (en)
Inventor
Bernd Buettelmann
Roland Jakob-Roetne
Andrew Thomas
Henner Knust
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009014001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009014001A publication Critical patent/MX2009014001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de isoxazol-imidazol que poseen una afinidad y selectividad para el sitio de unión del receptor de GABA A a5, con su elaboración, composiciones farmacéuticas que las contienen y su uso como medicamentos. Los compuestos activos de la presente invención son útiles como potenciadotes cognitivos o para el tratamiento de trastornos cognitivos como la enfermedad de Alzheimer. En particular, la presente invención está relacionada con derivados de aril-4-il-imidazol de fórmula I (ver figura) en la que R1, R2, y R3 son como se ha descrito en la especificación.
MX2009014001A 2007-06-22 2008-06-12 Derivados de isoxazol-imidazol. MX2009014001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110846 2007-06-22
PCT/EP2008/057384 WO2009000662A1 (en) 2007-06-22 2008-06-12 Isoxazole-imidazole derivatives

Publications (1)

Publication Number Publication Date
MX2009014001A true MX2009014001A (es) 2010-01-28

Family

ID=39735035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014001A MX2009014001A (es) 2007-06-22 2008-06-12 Derivados de isoxazol-imidazol.

Country Status (17)

Country Link
US (1) US7851469B2 (es)
EP (1) EP2170873B1 (es)
JP (1) JP5416103B2 (es)
KR (1) KR101228194B1 (es)
CN (1) CN101965344B (es)
AR (1) AR067075A1 (es)
AT (1) ATE519760T1 (es)
AU (1) AU2008267894B2 (es)
BR (1) BRPI0814718A2 (es)
CA (1) CA2690975A1 (es)
CL (1) CL2008001820A1 (es)
ES (1) ES2369805T3 (es)
IL (1) IL202667A0 (es)
MX (1) MX2009014001A (es)
PE (1) PE20090839A1 (es)
TW (1) TW200911795A (es)
WO (1) WO2009000662A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001237A2 (pt) 2010-07-19 2016-05-17 Syngenta Participations Ag compostos de isoxazola, isoatiazola, furano e tiofeno como microbicidas
US20130210836A1 (en) 2010-07-19 2013-08-15 Syngenta Crop Protection Llc Microbicides
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
KR20150033678A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
US20210084900A1 (en) 2017-05-04 2021-03-25 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for Combating Phytopathogenic Fungi
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
WO2001034603A2 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EA005934B1 (ru) 2001-07-05 2005-08-25 Х. Лундбекк А/С Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн
EP1448561B1 (en) 2001-11-20 2008-02-20 Eli Lilly And Company Beta 3 adrenergic agonists
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
WO2004022555A1 (en) 2002-09-06 2004-03-18 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
ES2887054T3 (es) * 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
EP1773807A2 (en) 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
US7351724B2 (en) 2004-10-15 2008-04-01 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
EP1832584B1 (en) * 2004-12-28 2011-12-21 ASKA Pharmaceutical Co., Ltd. Pyrimidinylisoxazole derivative
ATE537171T1 (de) * 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
CN101351461B (zh) * 2005-12-27 2011-09-07 弗·哈夫曼-拉罗切有限公司 芳基-异*唑-4-基-咪唑衍生物
RU2426732C2 (ru) * 2006-01-17 2011-08-20 Ф. Хоффманн-Ля Рош Аг АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1,2-a]ПИРИДИН, ПРИГОДНЫЙ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА ЧЕРЕЗ ПОСРЕДСТВО GABA-РЕЦЕПТОРОВ

Also Published As

Publication number Publication date
CL2008001820A1 (es) 2009-05-29
AR067075A1 (es) 2009-09-30
WO2009000662A1 (en) 2008-12-31
BRPI0814718A2 (pt) 2015-02-24
AU2008267894A1 (en) 2008-12-31
IL202667A0 (en) 2010-06-30
CN101965344B (zh) 2013-03-06
PE20090839A1 (es) 2009-07-02
CN101965344A (zh) 2011-02-02
ATE519760T1 (de) 2011-08-15
KR101228194B1 (ko) 2013-01-30
TW200911795A (en) 2009-03-16
JP5416103B2 (ja) 2014-02-12
CA2690975A1 (en) 2008-12-31
ES2369805T3 (es) 2011-12-07
JP2010530862A (ja) 2010-09-16
EP2170873A1 (en) 2010-04-07
EP2170873B1 (en) 2011-08-10
US20090005370A1 (en) 2009-01-01
US7851469B2 (en) 2010-12-14
KR20100023042A (ko) 2010-03-03
AU2008267894B2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2009014001A (es) Derivados de isoxazol-imidazol.
MX2011011489A (es) Derivados de isoxazol-piridina.
MX2011011477A (es) Derivados de isoxazol-piridazina.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
MX2011011273A (es) Derivados de isoxazol-pirazol.
EA200901373A1 (ru) Аминогетероциклические соединения
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
WO2009010454A3 (en) Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
IL190867A0 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
WO2008080844A9 (en) Azaspiro derivatives
MX2010005753A (es) Derivados de isoxazolo-pirazina.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
JP2007509960A5 (es)
EP2535329A3 (en) Spiro-piperidine derivatives

Legal Events

Date Code Title Description
FG Grant or registration